First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia

Study Number
84119
Phase
1
Principal Investigator
Eunice Wang
Purpose

This first-in-human (FIH) dose escalation will determine the maximum tolerated dose (MTD) of KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed AML who have failed or are ineligible for any approved standard of care therapies, including HSCT.

Check your eligibility for this trial
Check now
Full Title

(KO-MEN-001) A Phase 1 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO 539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.Gov ID
NCT04067336

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.